The AHA today urged the Centers for Medicare & Medicaid Services to consider alternative payment solutions to promote beneficiary access to chimeric antigen receptor T-cell (CAR T) therapy and other new technologies that “offer extraordinary potential to save lives, but are also associated with extraordinary costs.” In a letter to CMS, AHA recommended immediate and longer-term actions to “promote beneficiary access to these therapies, set appropriate precedents for how they are handled in rating setting and preserve opportunities for additional payment options in the future.” On Friday, CMS proposed that Medicare cover CAR T therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria.

Related News Articles

Headline
Ways and Means Committee Chairman Richard Neal, D-Mass., and Energy and Commerce Committee Chairman Frank Pallone Jr., D-N.J., along with Ranking Members Kevin…
Headline
The AHA has extended the deadline to May 31 for organizations to submit applications for its 2019 Innovation Challenge.
Insights and Analysis
Hospital and health system leaders shared how they are driving innovation to advance health and the patient experience at this week’s 20th Annual Not-for-…
Headline
The House Budget Committee today held a hearing on the Congressional Budget Office’s recent report on key design components and considerations for policymakers…
Headline
Organizations that provide palliative or end-of-life care may apply through Aug. 16 for the 2020 Circle of Life Awards.
Insights and Analysis
Streamlined communication between health systems and investors was the catalyst for the first conference, and continues to be critically important 20 years…